Office of Technology Transfer & Business Development
MedImmune, LLC, the global biologics business for AstraZeneca, currently has over 100 research projects and clinical product candidates in its portfolio. It aims to deliver several promising new biologics to the market by continuing its leadership in the area of infectious diseases; playing a key role in inflammation, cancer, and autoimmune and respiratory diseases; and building on its expertise in other areas to create a world-class focus in neuroscience, cardiovascular, and gastrointestinal diseases.
In addition to its vast internal discovery capabilities, MedImmune actively seeks external partnering for licensing and collaboration agreements to develop potential targets and technologies. Please click here to view the April 29, 2010 presentation by MedImmune on the Jefferson campus about its partnership approach and needs.
In the News
No news currently.